Skip to main content
SpringerLink
Log in

Changing Therapeutic Regimens in Benign Prostatic Hyperplasia

Clinical and Economic Considerations

  • Review Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

There is some evidence that medication and minimally invasive treatments may preclude eventual surgical treatment, but the precise effect is difficult to estimate because of differences in the study populations and the relatively short study periods. As a result of the dynamic nature of BPH treatment and the lack of long term data, the cost effects of the introduction of the various new treatments are also difficult to assess. Given the aging of the population and the growing percentage of patients with BPH for whom any type of treatment can be considered, a considerable increase of total costs can be expected. Long term prospective studies are necessary to gain insight into the most cost-effective treatment for different patient groups.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Table I
Table II
Fig. 3
Table III
Fig. 4
Fig. 5
Table IV
Table V
Table VI
Table VII
Fig. 6

Similar content being viewed by others

References

  1. Berry SJ, Coffey DS, Walsh PC, et al. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474–9

    PubMed  CAS  Google Scholar 

  2. Isaacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. Prostate 1989; Suppl. 2: 33–50

    Google Scholar 

  3. Barry MJ, Fowler Jr FJ, O’Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992; 148 (5): 1549–57

    PubMed  CAS  Google Scholar 

  4. Cockett ATK, Aso Y, Chatelain C, et al., editors. Proceedings of the 1st International Consultation on Benign Prostatic Hyperplasia (BPH); 1991 Jun 26–27: Paris. Jersey: Scientific Communication International Ltd, 1992

    Google Scholar 

  5. Sagnier P-P, MacFarlane G, Richard F, et al. Results of an epidemiological survey using a modified American Urological Association symptom index for benign prostatic hyperplasia in France. J Urol 1994; 151: 1266–70

    PubMed  CAS  Google Scholar 

  6. Tan HY, Choo WC, Archibald C, et al. A community based study of prostatic symptoms in Singapore. J Urol 1997; 157: 890–3

    Article  PubMed  CAS  Google Scholar 

  7. Norman RW, Nickel JC, Fish D, et al. ’Prostate-related symptoms’ in Canadian men 50 years of age or older: prevalence and relationships among symptoms. Br J Urol 1994; 74: 542–50

    Article  PubMed  CAS  Google Scholar 

  8. Lee E, Park M-S, Shin C, et al. A high-risk group for prostatism: a population-based epidemiological study in Korea. Br J Urol 1997; 79: 736–41

    Article  PubMed  CAS  Google Scholar 

  9. Hunter DJW, Berra-Unamuno A, Martin-Gordo A. Prevalence of urinary symptoms and other urological conditions in Spanish men 50 years old or older. J Urol 1996; 155: 1965–70

    Article  PubMed  CAS  Google Scholar 

  10. Nacey JN, Morum P, Delahunt B. Analysis of the prevalence of voiding symptoms in Maori, Pacific Island, and Caucasian New Zealand men. Urology 1995; 46: 506–11

    Article  PubMed  CAS  Google Scholar 

  11. Bosch JLHR, Hop WCJ, Kirkels WJ, et al. The International Prostate symptom score in a community-based sample of men between 55 and 74 years of age: prevalence and correlation of symptoms with age, prostate volume, flow rate and residual urine volume. Br J Urol 1995; 75: 622–30

    Article  PubMed  CAS  Google Scholar 

  12. Madersbacher S, Haidinger G, Temml C, et al. Prevalence of lower urinary tract symptoms in Austria as assessed by an open survey of 2,096 men. Eur Urol 1998; 34: 136–41

    Article  PubMed  CAS  Google Scholar 

  13. Chute CG, Panser LA, Girman CJ, et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 1993; 150: 85–9

    PubMed  CAS  Google Scholar 

  14. Tsukamoto T, Kumamoto Y, Masumori N, et al. Prevalence of prostatism in Japanese men in a community-based study with comparison to a similar American study. J Urol 1995; 154: 391–5

    Article  PubMed  CAS  Google Scholar 

  15. Blanker MH, Groeneveld FPMJ, Prins A, et al. Strong effects of definition and nonresponse bias on prevalence rates of clinical benign prostatic hyperplasia: the Krimpen study of male urogenital tract problems and general health status. BJU Int 2000; 85 (6): 665–71

    Article  PubMed  CAS  Google Scholar 

  16. Girman CJ. Population-based studies of the epidemiology of benign prostatic hyperplasia. Br J Urol 1998; 82 Suppl. 1: 34–43

    PubMed  Google Scholar 

  17. Chancellor MB, Rivas DA. American Urological Association symptom index for women with voiding symptoms: lack of index specificity for benign prostate hyperplasia. J Urol 1993; 150: 1706–9

    PubMed  CAS  Google Scholar 

  18. Chai TC, Belville WD, McGuire EJ, et al. Specificity of the American Urological Association voiding symptom index: comparison of unselected and selected samples of both sexes. J Urol 1993; 150: 1710–3

    PubMed  CAS  Google Scholar 

  19. Lepor H, Machi G. Comparison of AUA symptom index in unselected males and females between fifty-five and seventy-nine years of age. Urology 1993; 42: 36–41

    Article  PubMed  CAS  Google Scholar 

  20. Chancellor MB, Rivas DA, Keeley FX, et al. Similarity of the American Urological Association symptom index among men with benign prostate hyperplasia (BPH), urethral obstruction not due to BPH and detrusor hyperreflexia without outlet obstruction. Br J Urol 1994; 74: 200–3

    Article  PubMed  CAS  Google Scholar 

  21. Yalla SV, Sullivan MP, Lecamwasam HS, et al. Correlation of American Urological Association symptom index with obstructive and nonobstructive prostatism. J Urol 1995; 153: 674–80

    Article  PubMed  CAS  Google Scholar 

  22. Stoevelaar HJ, Van de Beek C, Nijs HGT, et al. The symptom questionnaire for benign prostatic hyperplasia: an ambiguous indicator for an ambiguous disease. Br J Urol 1996; 77: 181–5

    Article  PubMed  CAS  Google Scholar 

  23. Anon. Data on surgical treatment of patients, discharged from hospital with benign prostatic hyperplasia as primary or secondary diagnosis, 1972–1997. Utrecht: National Register of Hospital Admissions (SIG), 1998

  24. Anon. Dutch population by marital status, age and sex; 1 January, 1972–1997. Voorburg/Heerlen: Statistics Netherlands (CBS), 1998

  25. Sejr T, Andersen TF, Madsen M, et al. Prostatectomy in Denmark: regional variation and the diffusion of medical technology 1977–1985. Scand J Urol Nephrol 1991; 25: 101–6

    Article  PubMed  CAS  Google Scholar 

  26. Lu-Yao GL, Barry MJ, Chang C-H, et al. Transurethral resection of the prostate among Medicare beneficiaries in the United States: time trends and outcomes. Urology 1994; 44: 692–9

    Article  PubMed  CAS  Google Scholar 

  27. Blomqvist P, Ekbom A, Carlsson P, et al. Benign prostatic hyperplasia in Sweden 1987 to 1994: changing patterns of treatment, changing patterns of costs. Urology 1997; 50: 214–20

    Article  PubMed  CAS  Google Scholar 

  28. Xia Z, Roberts RO, Schottenfeld D, et al. Trends in prostatectomy for benign prostatic hyperplasia among black and white men in the United States: 1980 to 1994. Urology 199; 53: 1154–9

  29. Semmens JB, Wisniewski ZS, Bass AJ, et al. Trends in repeat prostatectomy after surgery for benign prostatic disease: application of record linkage to healthcare outcomes. BJU Int 1999; 84: 972–5

    Article  PubMed  CAS  Google Scholar 

  30. Stoevelaar HJ. Management of benign prostatic hyperplasia: practice variation and appropriateness of care [dissertation]. Rotterdam: Erasmus University, 1996

    Google Scholar 

  31. Holtgrewe HL, Bay-Nielsen H, Carlsson P, et al. The economics of the management of lower urinary tract symptoms and benign prostatic hyperplasia. In: Denis L, Griffiths K, Khoury S, et al., editors. Proceedings of the 4th International Consultation on Benign Prostatic Hyperplasia (BPH); 1997 Jul 2–5: Paris. Plymouth: Health Publication Ltd, 1998: 61–81

    Google Scholar 

  32. Cockett ATK, Khoury S, Aso Y, et al., editors. Proceedings of the 2nd International Consultation on Benign Prostatic Hyperplasia (BPH); 1993 Jun 27–30: Paris. Jersey: Scientific Communication International Ltd, 1993

    Google Scholar 

  33. McConnell JD, Barry MJ, Bruskewitz RC, et al. Benign prostatic hyperplasia: diagnosis and treatment. Clinical practice guideline, number 8. Rockville (MD): Agency for Health Care Policy and Research (AHCPR), Public Health Service, US Department of Health and Human Services, 1994. AHCPR Publication No.: 94-0582

    Google Scholar 

  34. Cockett ATK, Khoury S, Aso Y, et al., editors. Proceedings of the 3rd International Consultation on Benign Prostatic Hyperplasia (BPH); 1995 Jun 26–28: Monaco. Jersey: Scientific Communication International Ltd, 1996

    Google Scholar 

  35. Denis L, Griffiths K, Khoury S, et al., editors. Proceedings of the 4th International Consultation on Benign Prostatic Hyperplasia (BPH); 1997 Jul 2–5: Paris. Plymouth: Health Publication Ltd, 1998

    Google Scholar 

  36. Libman E, Fichten CS. Prostatectomy and sexual function. Urology 1987; 29: 467–78

    Article  PubMed  CAS  Google Scholar 

  37. Fowler Jr FJ, Wennberg JE, Timothy RP, et al. Symptom status and quality of life following prostatectomy. JAMA 1988; 259: 3018–22

    Article  PubMed  Google Scholar 

  38. Roos NP, Wennberg JE, Malenka DJ, et al. Mortality and reoperation after open and transurethral resection of the prostate for benign prostatic hyperplasia. N Engl J Med 1989; 320: 1120–4

    Article  PubMed  CAS  Google Scholar 

  39. Mebust WK, Holtgrewe HL, Cockett ATK, et al. Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol 1989; 141 (2): 243–7

    PubMed  CAS  Google Scholar 

  40. Chute CG, Stephenson WP, Guess HA, et al. Benign prostatic hyperplasia: a population-based study. Eur Urol 1991; 20 Suppl. 2: 11–7

    PubMed  Google Scholar 

  41. Doll HA, Black NA, McPherson K, et al. Mortality, morbidity and complications following transurethral resection of the prostate for benign prostatic hypertrophy. J Urol 1992; 147: 1566–73

    PubMed  CAS  Google Scholar 

  42. Jardin A, Bensadoun H, Delauche-Cavallier MC, et al. Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 12-18 month assessment. BPHALF Group. Br J Urol 1993; 72 (5 Pt 1): 615–20

    Article  PubMed  CAS  Google Scholar 

  43. Lepor H. Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group. Urology 1995; 45: 406–13

    Article  PubMed  CAS  Google Scholar 

  44. Lepor H, Kaplan SA, Klimberg I, et al. Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. Multicenter Study Group. J Urol 1997; 157: 525–30

    Article  PubMed  CAS  Google Scholar 

  45. Lepor H. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group. Urology 1998; 51: 901–6

    Article  PubMed  CAS  Google Scholar 

  46. Lukacs B, Grange JC, McCarthy C, et al. Clinical uroselectivity: a 3-year follow-up in general practice. BPH Group in General Practice. Eur Urol 1998; 33 Suppl. 2: 28–33

    Article  PubMed  Google Scholar 

  47. Schulman CC, Cortvriend J, Jonas U, et al. Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicenter, open-label study. European Tamsulosin Study Group. Eur Urol 1999; 36: 609–20

    Article  PubMed  CAS  Google Scholar 

  48. Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996; 48: 398–405

    Article  PubMed  CAS  Google Scholar 

  49. Champault G, Patel JC, Bonnard AM. A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia. Br J Clin Pharmacol 1984; 18: 461–2

    Article  PubMed  CAS  Google Scholar 

  50. Berges RR, Windeler J, Trampisch H, et al. Randomised, placebo-controlled, double blind clinical trial of β-sitosterol in patients with benign prostatic hyperplasia. β-Sitosterol Study Group. Lancet 1995; 345: 1529–32

    Article  PubMed  CAS  Google Scholar 

  51. Descotes JL, Rambeaud JJ, Deschaseaux P, et al. Placebo-controlled evaluation of the efficacy and tolerability of Permixon® in benign prostatic hyperplasia after exclusion of placebo responders. Clin Drug Invest 1995; 9: 291–7

    Article  Google Scholar 

  52. Carraro J-C, Raynaud J-P, Koch G, et al. Comparison of phytotherapy (Permixon®) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate 1996; 29: 231–40

    Article  PubMed  Google Scholar 

  53. Wilt TJ, Ishani A, Stark G, et al. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA 1998; 280: 1604–9

    Article  PubMed  CAS  Google Scholar 

  54. Wilt TJ, MacDonald R, Ishani A. β-Sitosterol for the treatment of benign prostatic hyperplasia: a systematic review. BJU Int 1999; 83: 976–83

    Article  PubMed  CAS  Google Scholar 

  55. MacDonald R, Ishani A, Rutks I, et al. A systematic review of Cernilton for the treatment of benign prostatic hyperplasia. BJU Int 1999; 85: 836–41

    Article  Google Scholar 

  56. Lepor H, Sypherd D, Machi G, et al. Randomized double-blind study comparing the effectiveness of balloon dilation of the prostate and cystoscopy for the treatment of symptomatic benign prostatic hyperplasia. J Urol 1992; 147: 639–44

    PubMed  CAS  Google Scholar 

  57. Donatucci CF, Berger N, Kreder KJ, et al. Randomized clinical trial comparing balloon dilatation to transurethral resection of prostate for benign prostatic hyperplasia. Urology 1993; 42: 42–9

    Article  PubMed  CAS  Google Scholar 

  58. Chiou RK, Binard JE, Ebersole ME, et al. Randomized comparison of balloon dilation and transurethral incision for treatment of symptomatic benign prostatic hyperplasia. J Endourol 1994; 8: 221–4

    Article  PubMed  CAS  Google Scholar 

  59. Saporta L, Aridogan IA, Erlich N, et al. Objective and subjective comparison of transurethral resection, transurethral incision and balloon dilatation of the prostate: a prospective study. Eur Urol 1996; 29: 439–45

    PubMed  CAS  Google Scholar 

  60. Montorsi F, Galli L, Guazzoni G, et al. Transrectal microwave hyperthermia for benign prostatic hyperplasia: long-term clinical, pathological and ultrastructural patterns. J Urol 1992; 148: 321–5

    PubMed  CAS  Google Scholar 

  61. Venn SN, Montgomery BSI, Sheppard SA, et al. Microwave hyperthermia in benign prostatic hypertrophy: a controlled clinical trial. Br J Urol 1995; 76: 73–6

    PubMed  CAS  Google Scholar 

  62. Abbou C-C, Payan C, Viens-Bitker C, et al. Transrectal and transurethral hyperthermia versus sham treatment in benign prostatic hyperplasia: a double-blind randomized multicentre clinical trial. Br J Urol 1995; 76: 619–24

    Article  PubMed  CAS  Google Scholar 

  63. Montorsi F, Guazzoni G, Rigatti P, et al. Is there a role for transrectal microwave hyperthermia in the treatment of benign prostatic hyperplasia? A critical review of a six-year experience. J Endourol 1995; 9: 333–7

    Article  PubMed  CAS  Google Scholar 

  64. Fitzpatrick JM. A critical evaluation of technological innovations in the treatment of symptomatic benign prostatic hyperplasia. Br J Urol 1998; 81 Suppl. 1: 56–63

    PubMed  Google Scholar 

  65. Orandi A. Transurethral incision of the prostate. J Urol 1973; 110: 229–31

    PubMed  CAS  Google Scholar 

  66. Orandi A. A new method for treating prostatic hypertrophy [comment]. Geriatrics 1978; 33 (6): 58–60, 64-5

    PubMed  CAS  Google Scholar 

  67. Edwards L, Powell C. An objective comparison of transurethral resection and bladder neck incision in the treatment of prostatic hypertrophy. J Urol 1982; 128: 325–7

    PubMed  CAS  Google Scholar 

  68. Edwards LE, Bucknall TE, Pittam MR, et al. Transurethral resection of the prostate and bladder neck incision: a review of 700 cases. Br J Urol 1985; 57: 168–71

    Article  PubMed  CAS  Google Scholar 

  69. Hellström P, Lukkarinen O, Kontturi M. Bladder neck incision or transurethral electroresection for the treatment of urinary obstruction caused by a small benign prostate? A randomized urodynamic study. Scand J Urol Nephrol 1986; 20: 187–92

    Article  PubMed  Google Scholar 

  70. Li MK, Ng ASM. Bladder neck resection and transurethral resection of the prostate: a randomized prospective trial. J Urol 1987; 138: 807–9

    PubMed  CAS  Google Scholar 

  71. Orandi A. Transurethral incision of prostate compared with transurethral resection of prostate in 132 matching cases. J Urol 1987; 138: 810–5

    PubMed  CAS  Google Scholar 

  72. Dørflinger T, Øster M, Larsen JF, et al. Transurethral prostatectomy or incision of the prostate in the treatment of prostatism caused by small benign prostates. Scand J Urol Nephrol Suppl. 1987; 104: 77–81

    PubMed  Google Scholar 

  73. Christensen MM, Aagaard J, Madsen PO. Transurethral resection versus transurethral incision of the prostate: a prospective randomized study. Urol Clin North Am 1990; 17: 621–30

    PubMed  CAS  Google Scholar 

  74. Soonawalla PF, Pardanani DS. Transurethral incision versus transurethral resection of the prostate: a subjective and objective analysis. Br J Urol 1992; 70: 174–7

    Article  PubMed  CAS  Google Scholar 

  75. Dørflinger T, Jensen FS, Krarup T, et al. Transurethral prostatectomy compared with incision of the prostate in the treatment of prostatism caused by small benign prostate glands. Scand J Urol Nephrol 1992; 26: 333–8

    Article  PubMed  Google Scholar 

  76. Sirls LT, Ganabathi K, Zimmern PE, et al. Transurethral incision of the prostate: an objective and subjective evaluation of long-term efficacy. J Urol 1993; 150: 1615–21

    PubMed  CAS  Google Scholar 

  77. Riehmann M, Knes JM, Heisey D, et al. Transurethral resection versus incision of the prostate: a randomized, prospective study. Urology 1995; 45: 768–75

    Article  PubMed  CAS  Google Scholar 

  78. Barham CP, Pocock RD, James ED. Who needs a prostatectomy? Review of a waiting list. Br J Urol 1993; 72: 314–7

    PubMed  CAS  Google Scholar 

  79. Garraway WM, Armstrong C, Auld S, et al. Follow-up of a cohort of men with untreated benign prostatic hyperplasia. Eur Urol 1993; 24: 313–8

    PubMed  CAS  Google Scholar 

  80. Barry MJ, Fowler Jr FJ, Bin L, et al. The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists. J Urol 1997; 157: 10–5

    Article  PubMed  CAS  Google Scholar 

  81. Jacobsen SJ, Girman CJ, Guess HA, et al. Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men. J Urol 1996; 155: 595–600

    Article  PubMed  CAS  Google Scholar 

  82. Roehrborn CG. The placebo effect in the treatment of benign prostatic hyperplasia. In: Kirby R, McConnell JD, Fitzpatrick JM, et al., editors. Textbook of benign prostatic hyperplasia. Oxford: Isis Medical Media Ltd, 1996: 239–58

    Google Scholar 

  83. Nickel JC. Placebo therapy of benign prostatic hyperplasia: a 25-month study. Canadian PROSPECT Study Group. Br J Urol 1998; 81: 383–7

    Article  PubMed  CAS  Google Scholar 

  84. Sech SM, Montoya JD, Bernier PA, et al. The so-called ‘placebo effect’ in benign prostatic hyperplasia treatment trials represents partially a conditional regression to the mean induced by censoring. Urology 1998; 51: 242–50

    Article  PubMed  CAS  Google Scholar 

  85. Stoevelaar HJ, Redekop WK. Treatment of benign prostatic hyperplasia: an update of the AHCPR clinical practice guideline. Rotterdam: Erasmus University, 1998

    Google Scholar 

  86. Wasson JH, Reda DJ, Bruskewitz RC, et al. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. N Engl J Med 1995; 332: 75–9

    Article  PubMed  CAS  Google Scholar 

  87. Flanigan RC, Reda DJ, Wasson JH, et al. 5-Year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs Cooperative Study. J Urol 1998; 160: 12–7

    Article  PubMed  CAS  Google Scholar 

  88. Buzelin JM, Fonteyne E, Kontturi M, et al. Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). European Tamsulosin Study Group. Br J Urol 1997; 80: 597–605

    Article  PubMed  CAS  Google Scholar 

  89. Lee E, Lee C. Clinical comparison of selective and non-selective α1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. Br J Urol 1997; 80: 606–11

    Article  PubMed  CAS  Google Scholar 

  90. Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of α1-adrenoreceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999; 36: 1–13

    Article  PubMed  CAS  Google Scholar 

  91. Okada H, Kamidono S, Yoshioka T, et al. A comparative study of terazosin and tamsulosin for symptomatic benign prostatic hyperplasia in Japanese patients. BJU Int 2000; 85: 676–81

    Article  PubMed  CAS  Google Scholar 

  92. Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med 1996; 335: 533–9

    Article  PubMed  CAS  Google Scholar 

  93. Roehrborn CG. Meta-analysis of randomized clinical trials of finasteride. Urology 1998; 51 Suppl. 4A: 46–9

    Article  PubMed  CAS  Google Scholar 

  94. Dahlstrand C, Waldén M, Geirsson G, et al. Transurethral microwave thermotherapy versus transurethral resection for symptomatic benign prostatic obstruction: a prospective randomized study with a 2-year follow-up. Br J Urol 1995; 76: 614–8

    Article  PubMed  CAS  Google Scholar 

  95. D’Ancona FCH, Francisca EAE, Witjes WPJ, et al. High energy thermotherapy versus transurethral resection in the treatment of benign prostatic hyperplasia: results of a prospective randomized study with 1 year of follow-up. J Urol 1997; 158: 120–5

    Article  PubMed  Google Scholar 

  96. Ahmed M, Bell T, Lawrence WT, et al. Transurethral microwave thermotherapy (Prostatron™ version 2.5) compared with transurethral resection of the prostate for the treatment of benign prostatic hyperplasia: a randomized, controlled, parallel study. Br J Urol 1997; 79: 181–5

    Article  PubMed  CAS  Google Scholar 

  97. Cowles III RS, Kabalin JN, Childs S, et al. A prospective randomized comparison of transurethral resection to visual laser ablation of the prostate for the treatment of benign prostatic hyperplasia. Urology 1995; 46: 155–60

    Article  PubMed  Google Scholar 

  98. Anson K, Nawrocki J, Buckley J, et al. A multicenter, randomized, prospective study of endoscopic laser ablation versus transurethral resection of the prostate. Urology 1995; 46: 305–10

    Article  PubMed  CAS  Google Scholar 

  99. Jung P, Mattelaer P, Wolff JM, et al. Visual laser ablation of the prostate: efficacy evaluated by urodynamics and compared to TURP. Eur Urol 1996; 30: 418–23

    PubMed  CAS  Google Scholar 

  100. Horninger W, Janetschek G, Watson G, et al. Are contact laser, interstitial laser, and transurethral ultrasound-guided laserinduced prostatectomy superior to transurethral prostatectomy? Prostate 1997; 31: 255–63

    Article  PubMed  CAS  Google Scholar 

  101. Keoghane SR, Cranston DW, Lawrence KC, et al. The Oxford Laser Prostate Trial: a double-blind randomized controlled trial of contact vaporization of the prostate against transurethral resection; preliminary results. Br J Urol 1996; 77: 382–5

    Article  PubMed  CAS  Google Scholar 

  102. Tuhkanen K, Heino A, Ala-Opas M. Contact laser prostatectomy compared to TURP in prostatic hyperplasia smaller than 40 ml: six-month follow-up with complex urodynamic assessment. Scand J Urol Nephrol 1999; 33: 31–4

    PubMed  CAS  Google Scholar 

  103. Carter A, Sells H, Speakman M, et al. A prospective randomized controlled trial of hybrid laser treatment or transurethral resection of the prostate, with a 1-year follow-up. BJU Int 1999; 83: 254–9

    Article  PubMed  CAS  Google Scholar 

  104. Tuhkanen K, Heino A, Alaopas M. Hybrid laser treatment compared with transurethral resection of the prostate for symptomatic bladder outlet obstruction caused by a large benign prostate: a prospective, randomized trial with a 6-month follow-up. BJU Int 1999; 84: 805–9

    Article  PubMed  CAS  Google Scholar 

  105. Shingleton WB, Terrell F, Renfroe DL, et al. A randomized prospective study of laser ablation of the prostate versus transurethral resection of the prostate in men with benign prostatic hyperplasia. Urology 1999; 54: 1017–21

    Article  PubMed  CAS  Google Scholar 

  106. Gilling PJ, Mackey M, Cresswell M, et al. Holmium laser versus transurethral resection of the prostate: a randomized prospective trial with 1-year followup. J Urol 1999; 162: 1640–4

    Article  PubMed  CAS  Google Scholar 

  107. Shokeir AA, Al-Sisi H, Farage YM, et al. Transurethral prostatectomy: a prospective randomized study of conventional resection and electrovaporization in benign prostatic hyperplasia. Br J Urol 1997; 80: 570–4

    Article  PubMed  CAS  Google Scholar 

  108. Kaplan SA, Laor E, Fatal M, et al. Transurethral resection of the prostate versus transurethral electrovaporization of the prostate: a blinded, prospective comparative study with 1-year followup. J Urol 1998; 159: 454–8

    Article  PubMed  CAS  Google Scholar 

  109. Gallucci M, Puppo P, Perachino M, et al. Transurethral electrovaporization of the prostate vs transurethral resection: results of a multicentric, randomized clinical study on 150 patients. Eur Urol 1998; 33: 359–64

    Article  PubMed  CAS  Google Scholar 

  110. Küpeli S, Baltaci S, Soygür T, et al. A prospective randomized study of transurethral resection of the prostate and transurethral vaporization of the prostate as a therapeutic alternative in themanagement of men with BPH. Eur Urol 1998; 34: 15–8

    Article  PubMed  Google Scholar 

  111. Hammadeh MY, Fowlis GA, Singh M, et al. Transurethral electrovaporization of the prostate — a possible alternative to transurethral resection: a one-year follow-up of a prospective randomized trial. Br J Urol 1998; 81: 721–5

    Article  PubMed  CAS  Google Scholar 

  112. Ekengren J, Haendler L, Hahn RG. Clinical outcome 1 year after transurethral vaporization and resection of the prostate. Urology 2000; 55: 231–5

    Article  PubMed  CAS  Google Scholar 

  113. Bruskewitz R, Issa MM, Roehrborn CG, et al. A prospective, randomized 1-year clinical trial comparing transurethral needle ablation to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia. J Urol 1998; 159: 1588–94

    Article  PubMed  CAS  Google Scholar 

  114. Djavan B Roehrborn CG, Shariat S, et al. Prospective randomized comparison of high energy transurethral microwave thermotherapy versus alpha-blocker treatment of patients with benign prostatic hyperplasia. J Urol 1999; 161: 139–43

    Article  PubMed  CAS  Google Scholar 

  115. Djavan B, Larson TR, Blute ML, et al. Transurethral microwave thermotherapy: what role should it play versus medical management in the treatment of benign prostatic hyperplasia? Urology 1998; 52: 935–47

    Article  PubMed  CAS  Google Scholar 

  116. Costello AJ, Crowe HR, Jackson T, et al. A randomised single institution study comparing laser prostatectomy and transurethral resection of the prostate. Ann Acad Med Singapore 1995; 24: 700–4

    PubMed  CAS  Google Scholar 

  117. Abrams P. In support of pressure-flow studies for evaluating men with lower urinary tract symptoms. Urology 1994; 44: 153–5

    Article  PubMed  CAS  Google Scholar 

  118. McConnell JD. Why pressure-flow studies should be optional and not mandatory studies for evaluating men with benign prostatic hyperplasia. Urology 1994; 44: 156–8

    Article  PubMed  CAS  Google Scholar 

  119. Bosch JLHR. Urodynamic effects of various treatment modalities for benign prostatic hyperplasia. J Urol 1997; 158: 2034–44

    Article  PubMed  CAS  Google Scholar 

  120. Madersbacher S, Marberger M. Is transurethral resection of the prostate still justified? BJU Int 1999; 83: 227–37

    Article  PubMed  CAS  Google Scholar 

  121. Witjes WPJ, Robertson A, Rosier PFWM, et al. Urodynamic and clinical effects of noninvasive and minimally invasive treatments in elderly men with lower urinary tract symptoms stratified according to the grade of obstruction. Urology 1997; 50: 55–61

    Article  PubMed  CAS  Google Scholar 

  122. Jahnson S, Dalén M, Gustavsson G, et al. Transurethral incision versus resection of the prostate for small to medium benign prostatic hyperplasia. Br J Urol 1998; 81: 276–81

    Article  PubMed  CAS  Google Scholar 

  123. Aagaard J, Jonler M, Fuglsig S, et al. Total transurethral resection versus minimal transurethral resection of the prostate — a 10-year follow-up study of urinary symptoms, uroflowmetry and residual volume. Br J Urol 1994; 74: 333–6

    Article  PubMed  CAS  Google Scholar 

  124. Ilkjær LB, Lund L, Nielsen TK. Outcome of transurethral prostatectomy in men over 80 years. Scand J Urol Nephrol 1998; 32: 270–2

    Article  PubMed  Google Scholar 

  125. Neykov KG, Panchev P, Georgiev M. Late results after transurethral bladder neck incision. Eur Urol 1998; 33: 73–8

    Article  PubMed  CAS  Google Scholar 

  126. Andersen JT, Nickel JC, Marshall VR, et al. Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia. Urology 1997; 49: 839–45

    Article  PubMed  CAS  Google Scholar 

  127. McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998; 338: 557–63

    Article  PubMed  CAS  Google Scholar 

  128. Hudson PB, Boake R, Trachtenberg J, et al. Efficacy of finasteride ismaintained in patientswith benign prostatic hyperplasia treated for 5 years. North American Finasteride Study Group. Urology 1999; 53: 690–5

    Article  PubMed  CAS  Google Scholar 

  129. De Wildt MJAM, D’Ancona FCH, Hubregtse M, et al. Three-year followup of patients treated with lower energy microwave thermotherapy. J Urol 1996; 156: 1959–63

    Article  PubMed  Google Scholar 

  130. Hallin A, Berlin T. Transurethral microwave thermotherapy for benign prostatic hyperplasia: clinical outcome after 4 years. J Urol 1998; 159: 459–64

    Article  PubMed  CAS  Google Scholar 

  131. Glass JM, Bdesha AS, Witherow RO. Microwave thermotherapy: a long-term follow-up of 67 patients froma single centre. Br J Urol 1998; 81 (3): 377–82

    Article  PubMed  CAS  Google Scholar 

  132. Lau KO, Li MK, Foo KT. Long-term follow-up of transurethral microwave thermotherapy. Urology 1998; 52: 829–33

    Article  PubMed  CAS  Google Scholar 

  133. Dæhlin L, Frugård J. Three-year follow-up after transurethral microwave thermotherapy (TUMT) for benign prostatic hyperplasia using the PRIMUS U + R device. Scand J Urol Nephrol 1999; 33: 217–21

    Article  PubMed  Google Scholar 

  134. Keijzers GBJM, Francisca EAE, D’Ancona FCH, et al. Long-term results of lower energy transurethral microwave thermotherapy. J Urol 1998; 159: 1966–73

    Article  PubMed  CAS  Google Scholar 

  135. Francisca EA, Keijzers GB, D’Ancona FC, et al. Lower-energy thermotherapy in the treatment of benign prostatic hyperplasia: long-term follow-up results of a multicenter international study. World J Urol 1999; 17: 279–84

    Article  PubMed  CAS  Google Scholar 

  136. Chertin B, Moriel EZ, Hadas-Halperin I, et al. Laser prostatectomy: long-term follow-up of 303 patients. Eur Urol 1999; 35: 285–8

    Article  PubMed  CAS  Google Scholar 

  137. Kabalin JN, Bite G, Doll S. Neodymium: YAG laser coagulation prostatectomy: 3 years of experience with 227 patients. J Urol 1996; 155: 181–5

    Article  PubMed  CAS  Google Scholar 

  138. Keoghane SR, Lawrence KC, Gray AM, et al. A double-blind randomized controlled trial and economic evaluation of transurethral resection vs contact laser vaporization for benign prostatic enlargement: a 3-year follow-up. BJU Int 2000; 85: 74–8

    Article  PubMed  CAS  Google Scholar 

  139. Hammadeh MY, Madaan S, Singh M, et al. Two-year follow-up of a prospective randomised trial of electrovaporization versus resection of prostate. Eur Urol 1998; 34: 188–92

    Article  PubMed  CAS  Google Scholar 

  140. Steele GS, Sleep DJ. Transurethral needle ablation of the prostate: a urodynamic based study with 2-year follow up. J Urol 1997; 158: 1834–8

    Article  PubMed  CAS  Google Scholar 

  141. Zwergel U, Wullich B, Lindenmeir U, et al. Long-term results following transurethral resection of the prostate. Eur Urol 1998; 33: 476–80

    Article  PubMed  CAS  Google Scholar 

  142. Borboroglu PG, Kane CJ, Ward JF, et al. Immediate and post-operative complications of transurethral prostatectomy in the 1990s. J Urol 1999; 162: 1307–10

    Article  PubMed  CAS  Google Scholar 

  143. Uchida T, Ohori M, Soh S, et al. Factors influencing morbidity in patients undergoing transurethral resection of the prostate. Urology 1999; 53: 98–105

    Article  PubMed  CAS  Google Scholar 

  144. Melchior J, Valk WL, Foret JD, et al. Transurethral prostatectomy: computerized analysis of 2,223 consecutive cases. J Urol 1974; 112: 634–42

    PubMed  CAS  Google Scholar 

  145. Malenka DJ, Roos N, Fisher ES, et al. Further study of the increased mortality following transurethral prostatectomy: a chart-based analysis. J Urol 1990; 144: 224–8

    PubMed  CAS  Google Scholar 

  146. Andersen TF, Bronnum-Hansen H, Sejr T, et al. Elevated mortality following transurethral resection of the prostate for benign hypertrophy: but why? Med Care 1990; 28: 870–81

    Article  PubMed  CAS  Google Scholar 

  147. Sidney S, Quesenberry Jr CP, Sadler MC, et al. Reoperation and mortality after surgical treatment of benign prostatic hypertrophy in a large prepaid medical care program. Med Care 1992; 30: 117–25

    Article  PubMed  CAS  Google Scholar 

  148. Concato J, Horwitz RI, Feinstein AR, et al. Problems of comorbidity in mortality after prostatectomy. JAMA 1992; 267: 1077–82

    Article  PubMed  CAS  Google Scholar 

  149. Crowley AR, Horowitz M, Chan E, et al. Transurethral resection of the prostate versus open prostatectomy: long-term mortality comparison. J Urol 1995; 153: 695–7

    Article  PubMed  CAS  Google Scholar 

  150. Krousel-Wood MA, Abdoh A, Re R. Comparing comorbid-illness indices assessing outcome variation: the case of prostatectomy. J Gen Intern Med 1996; 11: 32–8

    Article  PubMed  CAS  Google Scholar 

  151. Fuglsig S, Aagaard J, Jønler M, et al. Survival after transurethral resection of the prostate: a 10-year follow-up. J Urol 1994; 151: 637–9

    PubMed  CAS  Google Scholar 

  152. Cattolica EV, Sidney S, Sadler MC. The safety of transurethral prostatectomy: a cohort study of mortality in 9,416 men. J Urol 1997; 158: 102–4

    Article  PubMed  CAS  Google Scholar 

  153. Hargreave TB, Heynes CF, Kendrick SW, et al. Mortality after transurethral and open prostatectomy in Scotland. Br J Urol 1996; 77: 547–53

    Article  PubMed  CAS  Google Scholar 

  154. Kinn A-C, Helmy-Dhejne C, Larsson J. Sexual function one year after transurethral prostatic resection. Scand J Urol Nephrol 1998; 32: 33–5

    Article  PubMed  CAS  Google Scholar 

  155. Kunelius P, Häkkinen J, Lukkarinen O. Sexual functions in patients with benign prostatic hyperplasia before and after transurethral resection of the prostate. Urol Res 1998; 26: 7–9

    Article  PubMed  CAS  Google Scholar 

  156. Sengör F, Köse O, Yücebas E, et al. A comparative study of laser ablation and transurethral electroresection for benign prostatic hyperplasia: results of a 6-month follow-up. Br J Urol 1996; 78: 398–400

    Article  PubMed  Google Scholar 

  157. Ekengren J, Hahn RG. Complications during transurethral vaporization of the prostate. Urology 1996; 48: 424–7

    Article  PubMed  CAS  Google Scholar 

  158. Kaplan SA, Santarosa RP, Te AE. Transurethral electrovaporization of the prostate: one-year experience. Urology 1996; 48: 876–81

    Article  PubMed  CAS  Google Scholar 

  159. Matos-Ferreira A, Varregoso J. Electrovaporization of the prostate in patients with benign prostatic enlargement. Br J Urol 1997; 80: 575–8

    Article  PubMed  CAS  Google Scholar 

  160. Kaplan SA, Te AE. A comparative study of transurethral resection of the prostate using a modified electro-vaporizing loop and transurethral laser vaporization of the prostate. J Urol 1995; 154: 1785–90

    Article  PubMed  CAS  Google Scholar 

  161. Shingleton WB, Renfroe LD, Kolski JM, et al. A randomized prospective study of transurethral electrovaporization vs laser ablation of the prostate in men with benign prostatic hypertrophy. Scand J Urol Nephrol 1998; 32: 266–9

    Article  PubMed  CAS  Google Scholar 

  162. McCullough DL, Roth RA, Babayan RK, et al. Transurethral ultrasound-guided laser-induced prostatectomy: National Human Cooperative Study results. J Urol 1993; 150: 1607–11

    PubMed  CAS  Google Scholar 

  163. Takahashi S, Homma Y, Minowada S, et al. Transurethral ultrasound-guided laser-induced prostatectomy (TULIP) for benign prostatic hyperplasia: clinical utility at one-year follow-up and imaging analysis. Urology 1994; 43: 802–8

    Article  PubMed  CAS  Google Scholar 

  164. Bosch JLHR, Groen J, Schröder FH. Treatment of benign prostatic hyperplasia by transurethral ultrasound-guided laser-induced prostatectomy (TULIP): effects on urodynamic parameters and symptoms. Urology 1994; 44: 507–11

    Article  PubMed  CAS  Google Scholar 

  165. Sengör F, Erdogan K, Tuzluoglu D. Neodymium: YAG visual laser ablation of the prostate. Eur Urol 1996; 29: 446–9

    PubMed  Google Scholar 

  166. Gilling PJ, Cass CB, Malcolm A, et al. Holmium laser resection of the prostate versus neodymium: yttrium-aluminum-garnet visual laser ablation of the prostate: a randomized prospective comparison of two techniques for laser prostatectomy. Urology 1998; 51: 573–7

    Article  PubMed  CAS  Google Scholar 

  167. Roehrborn CG, Issa MM, Bruskewitz RC, et al. Transurethral needle ablation for benign prostatic hyperplasia: 12-month results of a prospective, multicenter U.S. study. Urology 1998; 51: 415–21

    Article  PubMed  CAS  Google Scholar 

  168. Marteinsson VT, Due J. Transurethral microwave thermotherapy for uncomplicated benign prostatic hyperplasia: a prospective study with emphasis on symptomatic improvement and complications. Scand J Urol Nephrol 1994; 28: 83–9

    Article  PubMed  CAS  Google Scholar 

  169. De la Rosette JJMCH, De Wildt MJAM, Höfner K, et al. High-energy thermotherapy in the treatment of benign prostatic hyperplasia: results of the European BPH Study Group. J Urol 1996; 156: 97–102

    Article  PubMed  Google Scholar 

  170. De Wildt MJ, Debruyne FM, De la Rosette JJ. High-energy transurethral microwave thermotherapy: a thermoablative treatment for benign prostatic obstruction. Urology 1996; 48 (3): 416–23

    Article  PubMed  Google Scholar 

  171. Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. Finasteride Study Group. N Engl J Med 1992; 327: 1185–91

    Article  PubMed  CAS  Google Scholar 

  172. Finasteride Study Group. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate 1993; 22: 291–9

    Article  Google Scholar 

  173. Nickel JC, Fradet Y, Boake RC, et al. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROSPECT Study Group. Can Med Assoc J 1996; 155: 1251–9

    CAS  Google Scholar 

  174. Marberger MJ. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind placebo-controlled, multicenter study. PROWESS Study Group. Urology 1998; 51: 677–86

    Article  PubMed  CAS  Google Scholar 

  175. Ware J, Sherbourne C. The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473–83

    Article  PubMed  Google Scholar 

  176. EuroQol Group. EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199–208

    Article  Google Scholar 

  177. Girman CJ, Jacobsen SJ, Tsukamoto T, et al. Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology 1998; 51: 428–36

    Article  PubMed  CAS  Google Scholar 

  178. Roberts RO, Jacobsen SJ, Rhodes T, et al. Natural history of prostatism: impaired health states in men with lower urinary tract symptoms. J Urol 1997; 157: 1711–7

    Article  PubMed  CAS  Google Scholar 

  179. Fowler Jr FJ, Barry MJ. Quality of life assessment for evaluating benign prostatic hyperplasia treatments. Eur Urol 1993; 24 Suppl. 1: 24–7

    PubMed  Google Scholar 

  180. Barry MJ, Fowler Jr FJ, O’Leary MP, et al. Measuring disease-specific health status in men with benign prostatic hyperplasia. Med Care 1995; 33 (4 Suppl.): AS145–AS155

    PubMed  CAS  Google Scholar 

  181. Jenkinson C, Gray A, Doll H, et al. Evaluation of index and profile measures of health status in a randomized controlled trial: comparison of the Medical Outcomes Study 36-item Short Form Health Survey, EuroQol, and disease specific measures. Med Care 1997; 35: 1109–18

    Article  PubMed  CAS  Google Scholar 

  182. Rhodes PR, Krogh RH, Bruskewitz RC. Impact of drug therapy on benign prostatic hyperplasia-specific quality of life. Urology 1999; 53: 1090–8

    Article  PubMed  CAS  Google Scholar 

  183. Teillac P. Relief of BPO or improvement in quality of life? Eur Urol 1998; 34 Suppl. 2: 3–9

    Article  PubMed  Google Scholar 

  184. Goluboff ET, Olsson CA. Urologists on a tightrope: coping with a changing economy. J Urol 1994; 151: 1–4

    PubMed  CAS  Google Scholar 

  185. Jacobsen SJ, Girman CJ, Guess HA, et al. New diagnostic treatment guidelines for benign prostatic hyperplasia: potential impact in the United States. Arch Intern Med 1995; 155: 477–81

    Article  PubMed  CAS  Google Scholar 

  186. Holtgrewe HL, Ackermann R, Bay-Nielsen R, et al. Report from the Committee on the Economics of BPH. In: Cockett ATK, Khoury S, Aso Y, et al., editors. Proceedings of the 3rd International Consultation on Benign Prostatic Hyperplasia (BPH); 1995 Jun 26–28: Monaco. Jersey: Scientific Communication International Ltd, 1996: 53–70

    Google Scholar 

  187. Weis KA, Epstein RS, Huse DM, et al. The costs of prostatectomy for benign prostatic hyperplasia. Prostate 1993; 22: 325–34

    Article  PubMed  CAS  Google Scholar 

  188. Wilde MI, Goa KL. Finasteride: an update of its use in the management of symptomatic benign prostatic hyperplasia. Drugs 1999; 57: 557–81

    Article  PubMed  CAS  Google Scholar 

  189. Chapple CR, Issa MM, Woo H. Transurethral needle ablation (TUNA™): a critical review of radiofrequency thermal therapy in the management of benign prostatic hyperplasia. Eur Urol 1999; 35: 119–28

    Article  PubMed  CAS  Google Scholar 

  190. Dixon CM, Theune C. Evaluating the cost of lasers for the treatment of benign prostatic hyperplasia. J Endourol 1995; 9: 189–93

    Article  PubMed  CAS  Google Scholar 

  191. Holtgrewe HL, Ackermann R, Bay-Nielsen H, et al. The economics of BPH. In: Cockett ATK, Khoury S, Aso Y, et al., editors. Proceedings of the 2nd International Consultation on Benign Prostatic Hyperplasia (BPH); 1993 Jun 27–30: Paris. Jersey: Scientific Communication International Ltd, 1993: 35–45

    Google Scholar 

  192. Waldén M, Acosta S, Carlsson P, et al. A cost-effectiveness analysis of transurethral resection of the prostate and transurethral microwave thermotherapy for treatment of benign prostatic hyperplasia: two-year follow-up. Scand J Urol Nephrol 1998; 32: 204–10

    Article  PubMed  Google Scholar 

  193. Keoghane SR, Lawrence KC, Gray AM, et al. The Oxford Laser Prostate Trial: economic issues surrounding contact laser prostatectomy. Br J Urol 1996; 77: 386–90

    Article  PubMed  CAS  Google Scholar 

  194. Hillman AL, Schwartz JS, Willian MK, et al. The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia. Urology 1996; 47: 169–78

    Article  PubMed  CAS  Google Scholar 

  195. Lanes SF, Sulsky S, Walker AM, et al. A cost density analysis of benign prostatic hyperplasia. Clin Ther 1996; 18: 993–1004

    Article  PubMed  CAS  Google Scholar 

  196. Kabalin JN, Butler ED. Costs of minimally invasive laser surgery compared with transurethral electrocautery resection of the prostate. West J Med 1995; 162: 426–9

    PubMed  CAS  Google Scholar 

  197. Mueller EJ, Zeidman EJ, Desmond PM, et al. Reduction of length of stay and cost of transurethral resection of the prostate by early catheter removal. Br J Urol 1996; 78: 893–6

    Article  PubMed  CAS  Google Scholar 

  198. Chang PL, Huang ST, Wang TM, et al. Improvements in the efficiency of care after implementing a clinical-care pathway for transurethral prostatectomy. Br J Urol 1998: 81: 394–7

    Article  PubMed  CAS  Google Scholar 

  199. Lowe FC, McDaniel RL, Chmiel JJ, et al. Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia. Urology 1995; 46: 477–83

    Article  PubMed  CAS  Google Scholar 

  200. Cockrum PC, Finder SF, Ries AJ, et al. A pharmacoeconomic analysis of patients with symptoms of benign prostatic hyperplasia. Pharmacoeconomics 1997; 11 (6): 550–65

    Article  PubMed  CAS  Google Scholar 

  201. Albertsen PC, Pellissier JM, Lowe FC, et al. Economic analysis of finasteride: a model-based approach using data from the Proscar Long-Term Efficacy and Safety Study. Clin Ther 1999; 21: 1006–24

    Article  PubMed  CAS  Google Scholar 

  202. Baladi J-F, Menon D, Otten N. An economic evaluation of finasteride for treatment of benign prostatic hyperplasia. Pharmacoeconomics 1996; 9 (5): 443–54

    Article  PubMed  CAS  Google Scholar 

  203. Chirikos TN, Sanford E. Cost consequences of surveillance, medical management or surgery for benign prostatic hyperplasia. J Urol 1996; 155: 1311–6

    Article  PubMed  CAS  Google Scholar 

  204. Baltussen RMPM, Wielink G, Stoevelaar HJ, et al. The economic impact of introducing transurethral microwave thermotherapy in the treatment of benign prostatic hyperplasia: a scenario analysis. World J Urol 1998; 16: 142–7

    Article  PubMed  CAS  Google Scholar 

  205. Bruskewitz R. Management of symptomatic BPH in the US: who is treated and how? Eur Urol 1999; 36 Suppl. 3: 7–13

    Article  PubMed  Google Scholar 

  206. Lukacs B. Management of symptomatic BPH in France: who is treated and how? Eur Urol 1999; 36 Suppl. 3: 14–20

    Article  PubMed  Google Scholar 

  207. Berges RR, Pientka L. Management of the BPH syndrome in Germany: who is treated and how? Eur Urol 1999; 36 Suppl. 3: 21–7

    Article  PubMed  Google Scholar 

  208. McNicholas TA. Management of symptomatic BPH in the UK: who is treated and how? Eur Urol 1999; 36 Suppl. 3: 33–9

    Article  PubMed  Google Scholar 

  209. Tubaro A, Montanari E. Management of symptomatic BPH in Italy: who is treated and how? Eur Urol 1999; 36 Suppl. 3: 28–32

    Article  PubMed  Google Scholar 

  210. Jensen KM-E, Hedlund H. Management of benign prostatic hyperplasia in Scandinavia: a hospital questionnaire on pretreatment evaluation and treatment. The Scandinavian Urologic Association Subcommittee on Benign Prostatic Hyperplasia. Scand J Urol Nephrol 1998; 32: 26–32

    Article  PubMed  CAS  Google Scholar 

  211. McPherson K, Strong PM, Epstein A, et al. Regional variations in the use of common surgical procedures within and between England and Wales, Canada and the United States of America. Soc Sci Med 1981; 15A: 273–88

    Google Scholar 

  212. McPherson K, Wennberg JE, Hovind OB, et al. Small-area variations in the use of common surgical procedures: an international comparison of New England, England, and Norway. N Engl J Med 1982; 307: 1310–4

    Article  PubMed  CAS  Google Scholar 

  213. Chassin MR, Brook RH, Park RE, et al. Variation in the use of medical and surgical services by the Medicare population. N Engl J Med 1986; 314: 285–90

    Article  PubMed  CAS  Google Scholar 

  214. Gittelsohn A, Powe NR. Small area variations in health care delivery in Maryland. Health Serv Res 1995; 30: 295–317

    PubMed  CAS  Google Scholar 

  215. Stoevelaar HJ, Van de Beek C, Casparie AF, et al. Variation in diagnostics and treatment of benign prostatic hyperplasia in urological practice [in Dutch]. Ned Tijdschr Geneeskd 1996; 140: 837–42

    PubMed  CAS  Google Scholar 

  216. Stoevelaar HJ, Van de Beek C, Casparie AF, et al. Treatment choice for benign prostatic hyperplasia: a matter of urologist preference? J Urol 1999; 161: 133–8

    Article  PubMed  CAS  Google Scholar 

  217. Stoevelaar HJ, McDonnell J, Van de Beek C, et al. Appropriate treatment of benign prostatic hyperplasia: enhancing the indication for treatment by systematic analysis of expert opinion [in Dutch]. Ned Tijdschr Geneeskd 1999; 143: 2425–9

    PubMed  CAS  Google Scholar 

  218. Stoevelaar HJ, McDonnell J, Bosch JLHR, et al. Appropriate treatment of benign prostatic hyperplasia: a European panel study. Leiden: RAND Europe, 1999. Report No.: RE 99.017

    Google Scholar 

  219. Bosch JLHR. Conservative non-instrumental treatment of benign prostatic hyperplasia. Urol Res 1997; 25 Suppl. 2: S107–S114

    Article  Google Scholar 

  220. Barry MJ, Williford WO, Chang Y, et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol 1995; 154: 1770–4

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute for Health Care Policy and Management, Erasmus University, PO Box 1738, 3000 DR, Rotterdam, The Netherlands

    Herman J. Stoevelaar & Joseph McDonnell

Authors
  1. Herman J. Stoevelaar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joseph McDonnell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Herman J. Stoevelaar.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stoevelaar, H.J., McDonnell, J. Changing Therapeutic Regimens in Benign Prostatic Hyperplasia. Pharmacoeconomics 19, 131–153 (2001). https://doi.org/10.2165/00019053-200119020-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200119020-00003

Keywords

Search

Navigation